Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
Bristol-Myers Squibb (NYSE:BMY) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases.
During the most recent period, it announced a multibillion-dollar financial investment to establish a multimodal manufacturing campus located in Texas, while also securing an accelerated regulatory approval from the FDA for a combination therapy intended to treat multiple myeloma.
Novo Nordisk (NYSE:NVO) earns most of its revenue by manufacturing and globally distributing medical treatments for diabetes and obesity.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.